At CAGE Bio, we are dedicated to advancing the treatment of immune-mediated skin conditions through our innovative Ionic Liquid platform. Our pipeline focuses on groundbreaking therapies for Atopic Dermatitis, Alopecia Areata, and Vitiligo, addressing significant unmet medical needs in dermatology. With a strong commitment to research and development, we aim to deliver safe, highly effective, and targeted solutions that improve patients’ lives and redefine skin health.
Atopic dermatitis, commonly known as eczema, is a chronic inflammatory skin condition characterized by itchy, red, and scaly skin. It is a common condition, affecting around 10-30% of children and 2-10% of adults.
Alopecia areata is an autoimmune condition that causes hair loss in distinct, round patches on the scalp, face, and sometimes other areas of the body.
Vitiligo is a chronic autoimmune disease that causes white patches to appear on the skin. It can also affect hair and the inside of the mouth.
Efficacy vs. Revenue – a comparison of leading topicals in the market
Copyright © 2020 CAGE Bio Inc. - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.
CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis